Investing in CRISPR Therapeutics AG (CRSP)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)54601.5297595
Intrinsic value (DCF)19.58-65
Graham-Dodd Method0.00-100
Graham Formula0.00-100

Company description

CRISPR Therapeutics AG (CRSP) is a biotechnology company that specializes in developing transformative gene-based medicines for serious diseases. The company was founded in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics uses CRISPR-Cas9 gene editing technology, which allows for precise and efficient modifications to the genetic code. This technology has the potential to revolutionize the treatment of genetic diseases by correcting or modifying faulty genes. The company has a strong pipeline of potential therapies for diseases such as beta thalassemia, sickle cell disease, and cancer. CRISPR Therapeutics has also formed strategic partnerships with other biotechnology and pharmaceutical companies to advance their research and development efforts. In 2020, the company received approval from the US FDA for the first-ever CRISPR-based therapy, marking a major milestone in the field of gene editing. CRISPR Therapeutics is dedicated to transforming the lives of patients and has a promising future ahead as it continues to innovate and develop groundbreaking treatments for serious diseases worldwide.